Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
The company could soon be swallowed by a very large peer — which also happens to be a business partner. Clinical-stage biotech Protagonist Therapeutics (PTGX 29.77%) was all the rage on the stock market Friday. The company’s share price closed a dizzying 29.8% higher on the day, thanks to intense takeover speculation. That leap was…